Evidence map›Paper›PMID 30191024›Full record

ReviewHepatic oncology2016

Liver cancer screening in high-risk populations.

Morris Sherman

Abstract readReview
In one paragraph

Review in Hepatic oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Morris ShermanDepartment of Medicine, University of Toronto, ON M5S 1A8, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with liver disease have a risk of developing hepatocellular carcinoma (HCC), but the risk varies between different diseases and is also different according to several other variables, such as age, type of underlying liver disease and severity of disease. Several risk scores have been developed to more adequately quantitate HCC risk in individual patients. Each risk score is applicable to a specific population (chronic hepatitis B or C, patients on the transplant list, cirrhosis in general, and so on). Most publications on risk scores do not provide clear guidance as to what level of measured risk is sufficient to trigger surveillance.

Identifiers

PMID30191024
PMCPMC6095323

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.